alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7423 Reported in Senate (RS)]

<DOC>

                                                       Calendar No. 468
118th CONGRESS
  2d Session
                                H. R. 7423

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 8, 2024

Received; read twice and referred to the Committee on Homeland Security 
                        and Governmental Affairs

                             August 1, 2024

               Reported by Mr. Peters, without amendment

_______________________________________________________________________

                                 AN ACT

 
 To designate the facility of the United States Postal Service located 
 at 103 Benedette Street in Rayville, Louisiana, as the ``Luke Letlow 
                        Post Office Building''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. LUKE LETLOW POST OFFICE BUILDING.

    (a) Designation.--The facility of the United States Postal Service 
located at 103 Benedette Street in Rayville, Louisiana, shall be known 
and designated as the ``Luke Letlow Post Office Building''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``Luke 
Letlow Post Office Building''.
                                                       Calendar No. 468

118th CONGRESS

  2d Session

                               H. R. 7423

_______________________________________________________________________

                                 AN ACT

 To designate the facility of the United States Postal Service located 
 at 103 Benedette Street in Rayville, Louisiana, as the ``Luke Letlow 
                        Post Office Building''.

_______________________________________________________________________

                             August 1, 2024

                       Reported without amendment
```
§ 520.1618 Orbifloxacin suspension. ( a ) *Specifications.* Each milliliter of suspension contains 30 milligrams (mg) orbifloxacin.
( b ) *Sponsor.* See No. 000061 in 510.600(c) of this chapter.
( c ) *Special considerations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals.
( d ) *Conditions of use* — ( 1 ) *Dogs* — ( i ) *Amount.* 1.1 to 3.4 mg/lb (2.5 to 7.5 mg/kg) of body weight once daily.
( ii ) *Indications for use.* For the treatment of urinary tract infections (cystitis) in dogs caused by susceptible strains of *Staphylococcus pseudintermedius*, *Proteus mirabilis*, *Escherichia coli,* and *Enterococcus faecalis* and skin and soft tissue infections (wounds and abscesses) in dogs caused by susceptible strains of *Staphylococcus pseudintermedius*, *Staphylococcus aureus*, coagulase-positive staphylococci, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas* spp., *Klebsiella pneumoniae*, *E. coli*, *Enterobacter* spp., *Citrobacter* spp., *E. faecalis*, β-hemolytic streptococci (Group G), and *Streptococcus equisimilis.*
( 2 ) *Cats* — ( i ) *Amount.* 3.4 mg/lb (7.5 mg/kg) of body weight once daily.
( ii ) *Indications for use.* For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of *S. aureus*, *E. coli*, and *P. multocida.*
[75 FR 26646, May 12, 2010]
EX-10.1



 Exhibit 10.1 

Second Amendment to 

Lantheus Holdings, Inc. 

2015 Equity Incentive Plan 

This Amendment (this “Amendment”) to the Lantheus Holdings, Inc. 2015 Equity Incentive Plan, as in effect from time to time
(the “Plan”), is dated as of April 27, 2017. 
 WHEREAS, pursuant to Section 16.2 of the Plan, the Board desires
to amend Section 4.1 of the Plan to increase the maximum number of shares of Common Stock that may be issued pursuant to Awards under the Plan; 

NOW THEREFORE, it is hereby acknowledged and agreed that: 
  

	 	1.	Defined Terms. Capitalized terms used herein, but not otherwise defined herein, have the respective meanings ascribed to them in the Plan. 


 

	 	2.	Amendment. Section 4.1 of the Plan shall be, and is, hereby amended and restated in its entirety as follows: 


Number of Shares Reserved. Subject to adjustment as provided in Section 4.5 hereof and subject to Section 15.10 hereof, the
total number of shares of Common Stock that are reserved for issuance under the Plan shall be 5,755,277 (the “Share Reserve”); provided, that no more than twenty percent of the Share Reserve may be granted as Incentive Stock
Options, subject to adjustment as provided in Section 4.5 hereof and the provisions of Sections 422 or 424 of the Code and any successor provisions; provided, further, that nothing in this Plan requires any percentage of Awards
(or Shares underlying Awards) to be granted as Incentive Stock Options. Each share of Common Stock subject to an Award shall reduce the Share Reserve by one share; provided, that Awards that are required to be paid in cash pursuant to their
terms shall not reduce the Share Reserve. Any shares of Common Stock delivered under the Plan shall consist of authorized and unissued shares or treasury shares. 
  

	 	3.	Reference to and Effect on the Plan. Except as specifically amended hereby, the Plan shall remain in full force and effect and otherwise unmodified. All references in the Plan to the “Plan” shall mean
the Plan as amended hereby. 

  

	 	4.	Effectiveness. This Amendment is effective as of the date first written above. 


* * *
§ 520.2240a Sulfaethoxypyridazine solution. ( a ) *Specifications.* Each milliliter of solution contains 62.5 milligrams (mg) sodium sulfaethoxypyridazine.
( b ) *Sponsor.* See No. 054771 § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.650 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Swine* — ( i ) *Amount.* Administer 3.8 grams per gallon for first day followed by 1.9 grams per gallon for not less than 3 days nor more than 9 days. Use as the sole source of sulfonamide.
( ii ) *Indications for use.* For treatment of bacterial scours pneumonia enteritis, bronchitis, septicemia accompanying *Salmonella choleraesuis* infection.
( iii ) *Limitations.* Do not treat within 10 days of slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Cattle* — ( i ) *Amount.* For use at 2.5 grams per gallon. Administer at the rate of 1 gallon per 100 pounds of body weight per day for 4 days. Use as the sole source of sulfonamide.
( ii ) *Indications for use.* For treatment of respiratory infections (pneumonia, shipping fever), foot rot, calf scours; and as adjunctive therapy in septicemia accompanying mastitis and metritis.
( iii ) *Limitations.* Do not treat within 16 days of slaughter. Milk that has been taken from animals during treatment and for 72 hours (6 milkings) after latest treatment must not be used for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 28830, May 20, 2014]
NOAA Technical=20Memorandum
Exhibit 32.1

 

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Champion Enterprises, Inc. (the “Company”) on Form 10-Q for the period ending April 2, 2005 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, William C. Griffiths, Chief Executive Officer of the Company, and Phyllis A. Knight, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and                                |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |

 

 
| /s/  WILLIAM C. GRIFFITHS  |
|----------------------------|
| William C. Griffiths       |
| Chief Executive Officer    |
| Champion Enterprises, Inc. |
| April 22, 2005             |
|                       |
| /s/  PHYLLIS A. KNIGHT     |
| Phyllis A. Knight          |
| Chief Financial Officer    |
| Champion Enterprises, Inc. |
| April 22, 2005             |
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr., Chief Justice

Michael F. Cavanagh

Marilyn Kelly

Stephen J. Markman

Diane M. Hathaway

Mary Beth Kelly

Brian K. Zahra, Justices

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

 _________________________________________

 Clerk

November 20, 2012

h1113

Order 

November 20, 2012

145674

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff-Appellee,

v SC: 145674

COA: 309615

Kent CC: 04-004011-FC

JAMES DONALD MOORE, 04-004013-FC

Defendant-Appellant.

_________________________________________/

On order of the Court, the application for leave to appeal the May 25, 2012 order 

of the Court of Appeals is considered, and it is DENIED, because the defendant’s motion 

for relief from judgment is prohibited by MCR 6.502(G).
----

|   | (1) | In connection with the Annual Report of the Company on form 10-K for the twelve month period ended May 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), fully complies with the requirements of Section 13(a) and Section 15(d) of the Securities and Exchange Act of 1934; and |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company for the periods presented therein. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | By:                      | /ss/ Irene Posio             |
|--------|--------------------------|------------------------------|
|   |                     | Irene Posio                  |
|   |                     | Senior Corporate Controller  |
|   |                     | Principal Accounting Officer |
|   |                     |                         |
|   | Date: September 14, 2009 |

----
EXHIBIT 32

CERTIFICATION 
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Teachers Insurance
and Annuity Association of America, do hereby certify, to such officers knowledge, that:

The annual report on Form 10-K of the TIAA Real Estate Account (the Account) for the year ended December 31, 2005 (the Form 10-K) fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Account.

|Dated: March 14, 2006 |  | /s/ Herbert M. Allison, Jr.                      
|--------------------- |  | -------------------------------------------------
|                      |  |                                                  
|                      |  | Herbert M. Allison, Jr.                          
|                      |  | Chairman of the Board, President and Chief       
|                      |  | Executive Officer, Teachers Insurance and Annuity
|                      |  | Association of America                           
|                     
|Dated: March 14, 2006 |  | /s/ Russell Noles                                
|                      |  |                                                  
|                      |  | Russell Noles                                    
|                      |  | Vice President and Acting                        
|                      |  | Chief Financial Officer, Teachers Insurance and  
|                      |  | Annuity Association of America                   

A signed original of this written statement required by Section 906 has been provided to the TIAA Real Estate Account and will be retained by the Account and furnished to the Securities and Exchange
Commission or its staff upon request.

---









| | A11007
    (4/06) | 
| | ----------------- | 
| |                   | 
| |                   | 

---
§ 520.1196 Ivermectin and pyrantel tablets. ( a ) *Specifications.* Each chewable tablet contains either 68 micrograms (μg) of ivermectin and 57 milligrams (mg) of pyrantel (as pamoate salt), or 136 μg and 114 mg, or 272 μg and 227 mg, respectively.
( b ) *Sponsors.* See Nos. 000010, 051311, and 053701 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Dogs* — ( i ) *Amount.* Administer a minimum of 6 μg of ivermectin and 5 mg of pyrantel per kilogram (2.72 μg and 2.27 mg per pound) of body weight monthly.
( ii ) *Indications for use.* To prevent canine heartworm disease by eliminating the tissue larval stages of *Dirofilaria immitis* for up to a month (30 days) after infection and treatment and control of adult roundworms *Toxocara canis* and *Toxascaris leonina,* and adult hookworms *Ancylostoma caninum, A. braziliense,* and *Uncinaria stenocephala.*
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) [Reserved]
[58 FR 8542, Feb. 16, 1993, as amended at 61 FR 15186, Apr. 5, 1996; 61 FR 59004, Nov. 20, 1996; 62 FR 63270, Nov. 28, 1997; 66 FR 35756, July 9, 2001; 67 FR 21996, May 2, 2002; 68 FR 55823, Sept. 29, 2003; 78 FR 28822, May 20, 2014; 84 FR 39183, Aug. 9, 2019; 88 FR 16547, Mar. 20, 2023; 89 FR 42357, May 15, 2024]
<TABLE> <S> <C>



<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF BAB HOLDINGS, INC. FOR THE YEAR ENDED NOVEMBER 30, 1996
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          NOV-30-1996
<PERIOD-END>                               NOV-30-1996
<CASH>                                       2,163,293
<SECURITIES>                                         0
<RECEIVABLES>                                1,478,098
<ALLOWANCES>                                    30,000
<INVENTORY>                                    103,314
<CURRENT-ASSETS>                             3,686,273
<PP&E>                                       3,833,027
<DEPRECIATION>                                 299,315
<TOTAL-ASSETS>                              11,147,987
<CURRENT-LIABILITIES>                        2,351,220
<BONDS>                                          8,133
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     9,218,522
<OTHER-SE>                                   (423,513)
<TOTAL-LIABILITY-AND-EQUITY>                11,147,987
<SALES>                                      3,484,319
<TOTAL-REVENUES>                             6,640,453
<CGS>                                        1,221,826
<TOTAL-COSTS>                                6,944,217
<OTHER-EXPENSES>                                12,550
<LOSS-PROVISION>                                37,828
<INTEREST-EXPENSE>                               4,530
<INCOME-PRETAX>                              (320,844)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (320,844)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (320,844)
<EPS-PRIMARY>                                   (0.04)
<EPS-DILUTED>                                   (0.04)
        




</TABLE>
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 9
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE FIRST
MARINER BANCORP DECEMBER 31, 1996 FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                       5,323,984
<INT-BEARING-DEPOSITS>                      27,186,076
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                     324875
<INVESTMENTS-CARRYING>                       1,099,000
<INVESTMENTS-MARKET>                         1,097,438
<LOANS>                                     95,763,637
<ALLOWANCE>                                (1,241,663)
<TOTAL-ASSETS>                             132,561,546
<DEPOSITS>                                 102,289,146
<SHORT-TERM>                                 6,000,000
<LIABILITIES-OTHER>                            476,398
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       131,363
<OTHER-SE>                                  23,664,639
<TOTAL-LIABILITIES-AND-EQUITY>             132,561,546
<INTEREST-LOAN>                              6,177,495
<INTEREST-INVEST>                              558,950
<INTEREST-OTHER>                                     0
<INTEREST-TOTAL>                             6,736,445
<INTEREST-DEPOSIT>                           2,999,102
<INTEREST-EXPENSE>                           3,107,336
<INTEREST-INCOME-NET>                        3,629,109
<LOAN-LOSSES>                                1,039,636
<SECURITIES-GAINS>                             330,030
<EXPENSE-OTHER>                              5,836,679
<INCOME-PRETAX>                            (2,173,319)
<INCOME-PRE-EXTRAORDINARY>                 (2,173,319)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (2,173,319)
<EPS-PRIMARY>                                   (1.71)
<EPS-DILUTED>                                   (1.71)
<YIELD-ACTUAL>                                    9.05
<LOANS-NON>                                  1,574,000
<LOANS-PAST>                                         0
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                960,000
<ALLOWANCE-OPEN>                               376,287
<CHARGE-OFFS>                                  248,192
<RECOVERIES>                                     73932
<ALLOWANCE-CLOSE>                            1,241,663
<ALLOWANCE-DOMESTIC>                           876,904
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                        364,759


</TABLE>
#### BICK, Appellant, v. UMSTATTD et al., Respondents.

St. Louis Court of Appeals.

Opinion Filed March 23, 1909.

JUDGMENTS: Appeals: Final Judgment. Where the trial court, after sustaining a motion to strike out the defendant’s answer, makes and enters a ruling to the effect that the petition does not state facts sufficient to constitute a cause of action against the defendant and orders dismissal of the case, this is not a final judgment from which an appeal will lie.

Appeal from Monroe Circuit *Court.*— Eon. *David E. Eby,*Judge.

Appeal dismissed.

*271
      *J. J. Bick, fro se,*and *T. P. Bashano*for appellant.

*Grant S. Watkins*for respondents.

REYNOLDS, P. J.

— This case comes to this court on an order or judgment in the following form:

> “Now on this second day of September, 1905, come the parties herein by their respective attorneys, and the motion heretofore filed by the plaintiff herein to strike out part of the third amended separate answer filed herein by defendant William Davis is taken up and is by the court sustained and the court upon its own motion rules that the petition filed herein is insufficient and does not state facts sufficient to constitute a cause of action against the defendants, wherefore the plaintiff declines and refuses'to plead further in this cause; and now on application of defendants this cause is by the court ordered dismissed.”

This is not a final judgment authorizing an appeal. Nothing follows this entry but a statement that the plaintiff files his application and affidavit for an appeal and the court, “having seen and heard said application and affidavit 'doth grant an appeal in this cause to the St. Louis Court of Appeals, and doth fix the bond in appeal herein at the sum of one hundred dollars, with leave to file the same within ten days after the adjournment of this term of court, subject to the approval of the clerk of this court.” It does not appear that a demurrer was filed by defendants to the petition, but the court, of its own motion, as will be seen by this order, “rules that the petition filed herein is insufficient and does not state facts sufficient to constitute a cause of action against the defendants, wherefore the plaintiff declines and refuses to plead further in this cause, and now, on application of defendants, this cause is by the court ordered dismissed.” As has been held in many cases, this is not a final judgment or decision, from *272which an appeal lies. [See Finkelnburg, Missouri Appellate Practice (2 Ed.), pp. 57 and following, and authorities collated in note on p. 63; also Lyons et al. v. Rollinson, 109 Mo. App. 68, and cases there collated; State ex rel. v. Turner, 113 Mo. App. 53; A. A. Cooper Wagon & B. Co. v. Cornell, 111 S. W. 521, 131 Mo. App. 344.] Appeal dismissed.

All concur.